By inhibiting IL-22, these agents may mitigate the inflammatory responses that contribute to lung tissue damage and COPD progression, highlighting the importance of TH-22 cells and IL-22 as novel therapeutic targets in managing COPD exacerbations [28, 29]. The gene discussed is IL22; the disease is chronic obstructive pulmonary disease.